Tear protein biomarkers of refractive surgery pain

Information

  • Research Project
  • 10249335
  • ApplicationId
    10249335
  • Core Project Number
    R61EY032468
  • Full Project Number
    5R61EY032468-02
  • Serial Number
    032468
  • FOA Number
    RFA-NS-18-041
  • Sub Project Id
  • Project Start Date
    9/1/2020 - 3 years ago
  • Project End Date
    8/31/2022 - a year ago
  • Program Officer Name
    ARAJ, HOUMAM H
  • Budget Start Date
    9/1/2021 - 2 years ago
  • Budget End Date
    8/31/2022 - a year ago
  • Fiscal Year
    2021
  • Support Year
    02
  • Suffix
  • Award Notice Date
    9/7/2021 - 2 years ago

Tear protein biomarkers of refractive surgery pain

PROJECT SUMMARY Photorefractive keratectomy (PRK) and laser-assisted in situ keratomileusis (LASIK) are surgical procedures used to correct refractive errors, with approximately 600,000 surgeries performed in the United States each year. A proportion (10 - 20%) of individuals develop persistent ocular pain after refractive surgery, which is a source of tremendous morbidity, limiting the ability to work, impacting mental health, and leading to suicidal ideation in severe cases. We hypothesize that proteins in the tear fluid modulate corneal nerve function, increasing the risk of and contributing to persistent pain after refractive surgery. As such, our studies will use proteomic analysis of tear fluid after surgery to identify diagnostic biomarkers for persistent ocular pain. We will also examine tear proteins prior to surgery in an effort to identify prognostic biomarkers that predict which individuals are likely to develop persistent pain after surgery. R33 Phase studies will use an alternative proteomics platform for analytical validation, and an additional new patient population for clinical validation. This knowledge can lead to better preventative and therapeutic algorithms to combat this debilitating condition and thus improve quality of life and decrease patient suffering.

IC Name
NATIONAL EYE INSTITUTE
  • Activity
    R61
  • Administering IC
    EY
  • Application Type
    5
  • Direct Cost Amount
    656482
  • Indirect Cost Amount
    217362
  • Total Cost
    873844
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    867
  • Ed Inst. Type
    SCHOOLS OF MEDICINE
  • Funding ICs
    NEI:873844\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    OREGON HEALTH & SCIENCE UNIVERSITY
  • Organization Department
    OTHER BASIC SCIENCES
  • Organization DUNS
    096997515
  • Organization City
    PORTLAND
  • Organization State
    OR
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    972393098
  • Organization District
    UNITED STATES